688426 Jiangsu Cowin Biotech
- 18.38
- +0.32+1.77%
Jiangsu Cowin Biotech News
Express News | Kangwei Century: Wholly-owned subsidiary's product Helicobacter pylori antigen test kit obtained registration certificates for three types of medical devices
Kangwei Century (688426.SH) issued 2023 annual results with a net loss of 84.4095 million yuan
Kangwei Century (688426.SH) released its 2023 annual report. The company achieved operating income of 1 during the reporting period...
Kangwei Century (688426.SH): A total cost of 10.166 million yuan to buy back 0.4333% of the shares
Gelonghui, April 1, 丨 Kang Wei Century (688426.SH) announced that by the close of trading on March 29, 2024, the company had repurchased 487,427 shares of the company through centralized bidding transactions, accounting for 0.4333% of the company's total share capital of 112,493,716 shares. The highest price of the repurchase transaction was 22.48 yuan/share, the lowest price was 20.01 yuan/share, and the total amount of capital paid was RMB 10,166,439.03 (excluding transaction fees such as stamp duty and transaction fees).
Kangwei Century (688426.SH): First repurchase of 59,000 shares
Gelonghui, March 4, 丨 Kang Wei Century (688426.SH) announced that on March 4, 2024, Jiangsu Kangwei Century Biotechnology Co., Ltd. repurchased 59,262 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0528% of the company's total share capital of 112,227,568 shares. The highest price for the repurchase transaction was 21.64 yuan/share, and the lowest price was 20.98 yuan/share. The total amount of capital paid was RMB 1,274,479.33.
Kangwei Century (688426): Molecular testing industry chain layout Helicobacter pylori stool test creates a second growth curve
Key investment points Investment logic: The traditional molecular testing business covers the entire “core materials+kit+testing service” business process, bringing steady growth; Helicobacter pylori drug resistance testing products are expected to be approved in 2024, bringing a second growth curve.
Kangwei Century (688426.SH): net loss of 81.013,600 yuan in 2023
Gelonghui, Feb. 27丨Kang Wei Century (688426.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 177.455,800 yuan, a year-on-year decrease of 65.98%; realized total profit of -86.773,900 yuan, a year-on-year decrease of 144.41%; realized net profit attributable to owners of the parent company - 81.013,600 yuan, a year-on-year decrease of 150.87%; realized net profit attributable to owners of the parent company - 116.5982 million yuan, a year-on-year decrease of 116.5982 million yuan, a year-on-year decrease of 116.5982 million yuan. 178.31%
Express News | Kangwei Century: Plans to buy back the company's shares for 30 million yuan to 60 million yuan
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) 37% Share Price Plunge Could Signal Some Risk
The Jiangsu CoWin Biotech Co., Ltd. (SHSE:688426) share price has fared very poorly over the last month, falling by a substantial 37%. For any long-term shareholders, the last month ends a year to
Kang Wei (688426.SH) issued a forecast loss. The net loss is expected to be 75 million yuan to 90 million yuan in 2023, changing from profit to loss over the same period last year
According to Zhitong Finance App News, Kang Wei Century (688426.SH) announced that the company expects to achieve a loss in 2023 net profit attributable to the owner of the parent company compared with the same period last year. The net profit attributable to the owner of the parent company is a loss of 75 million yuan to 90 million yuan, a decrease of 147.09% to 156.51% compared with the same period last year. Net profit attributable to owners of the parent company in 2022:15.9258,900 yuan. During the reporting period, it was affected by factors such as domestic and foreign macroeconomic environments, changes in health prevention and control policies, and changes in market demand in the molecular testing industry
Kangwei Century (688426.SH) released the first three quarter results, with a net loss of 355.46,400 yuan
Kangwei Century (688426.SH) released its report for the third quarter of 2023. The company achieved revenue of 1 in the first three quarters...
Kangwei Century (688426.SH) 11.753,900 restricted shares will be listed and distributed on October 25
Kang Wei Century (688426.SH) announced that the number of restricted shares currently listed and in circulation of the company is 11.753,900 shares...
Jiangsu Cowin Biotech's Unit Gets Nod for Registration of Blood Detection Kit
Jiangsu Cowin Biotech's (SHA:688426) unit, Jiangsu Jianwei Diagnostic Technology, received a registration certificate from the food and drug administration of China's Jiangsu Province for its fecal bl
Kang Wei Century (688426.SH): Fecal occult blood test kit (colloidal gold method) obtained a Class II medical device registration certificate
Kangwei Century (688426.SH) announced that Jiangsu Jianwei Diagnostic Technology Co., Ltd., a wholly-owned subsidiary of the company (“Jianwei...
Kang Wei Century (688426): Xiaolongtou, a raw material for molecular testing, digestive tract testing is the next blue ocean of development
Established in 2010, Kangwei Century is mainly engaged in the development and production of biological reagents with high added value and high technical content, and has realized the layout of reagents and services for the entire process of molecular testing, from preservation and purification of nucleic acid samples to testing. Company founder
Kang Wei Century (688426.SH) released the results for the first half of the year, with a net loss of 9.8736 million yuan, from profit to loss over the previous year
Kang Wei Century (688426.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) Stock Is Going Strong: Have Financials A Role To Play?
Most readers would already be aware that Jiangsu CoWin Biotech's (SHSE:688426) stock increased significantly by 13% over the past week. Given that stock prices are usually aligned with a company's f
The registration date for Kangwei Century (688426.SH) to distribute 5.2 yuan of 10 shares to 2 shares in 2022 is June 9
According to the Zhitong Finance App, Kangwei Century (688426.SH) announced that the company will implement the 2022 annual equity distribution, distribute a cash dividend of 0.52 yuan (tax included) per share, and transfer 0.2 shares per share to all shareholders using the Capital Provident Fund. The share registration date is June 9.
Jiangsu CoWin Biotech's (SHSE:688426) Solid Earnings May Rest On Weak Foundations
Jiangsu CoWin Biotech Co., Ltd.'s (SHSE:688426) healthy profit numbers didn't contain any surprises for investors. However the statutory profit number doesn't tell the whole story, and we have found
Kangwei Century (688426.SH) released first-quarter results, with net profit of 3,98894 million yuan, a year-on-year decrease of 89.74%
According to the Zhitong Finance App, Kang Weishi (688426.SH) released its report for the first quarter of 2023. The company's operating income during the reporting period was 76.943 million yuan, a decrease of 37.35% over the previous year; net profit attributable to shareholders of listed companies was 3.8894 million yuan, a decrease of 89.74% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 3.8594 million yuan; basic earnings per share 0.04 yuan.
Kangwei Century (688426.SH) announced its 2022 annual results, with net profit of 159 million yuan, an increase of 26.55% over the previous year. It plans to distribute 5.2 yuan from 10 shares to 2 shares
According to the Zhitong Finance App, Kang Weishi (688426.SH) disclosed its 2022 annual report. During the reporting period, the company achieved revenue of 522 million yuan, an increase of 54.11% over the previous year; Guimu's net profit of 159 million yuan, an increase of 26.55% over the previous year; after deducting non-net profit of 149 million yuan, an increase of 33.12% over the previous year; and basic earnings per share of 2.16 yuan. The company plans to distribute a cash dividend of 5.2 yuan (tax included) for every 10 shares, and transfer 2 shares for every 10 shares.
Analysis
Price Target
No Data
